SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-24-051803
Filing Date
2024-06-11
Accepted
2024-06-11 17:25:39
Documents
5
Period of Report
2024-07-29

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT ea0206592-04.htm DEF 14A 1357149
2 GRAPHIC tcadrenal_logo.jpg GRAPHIC 47165
3 GRAPHIC tcadrenal_logo1.jpg GRAPHIC 47150
4 GRAPHIC tproxy_001.jpg GRAPHIC 1085606
5 GRAPHIC tproxy_002.jpg GRAPHIC 857095
  Complete submission text file 0001213900-24-051803.txt   4164807
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41596 | Film No.: 241036819
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)